<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02501135</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 15-00396</org_study_id>
    <nct_id>NCT02501135</nct_id>
  </id_info>
  <brief_title>A Retrospective Investigation of Local Anesthetic Concentrations in Femoral Nerve Block</brief_title>
  <official_title>A Retrospective Investigation of Safety and Efficacy From Increasing Concentrations of Local Anesthetic in Pediatric Femoral Nerve Blocks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giorgio Veneziano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to retrospectively compare perioperative pain relief and safety
      in pediatric patients who have received a femoral nerve block with varying concentrations of
      local anesthetic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Local Anesthetic Injected for Femoral Nerve Block</measure>
    <time_frame>length of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total mg of Local Anesthetic Injected for Femoral Nerve Block</measure>
    <time_frame>length of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraoperative Tylenol Administered</measure>
    <time_frame>length of surgery</time_frame>
    <description>Amount of Tylenol administered based on if got ropivacaine or bupivacaine femeral nerve block.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-operative Opioids Administered</measure>
    <time_frame>in PACU (1 hr post-op)</time_frame>
    <description>Amount of opioid consumption in the post operative anesthesia care unit depending on if the patient received femoral nerve block with ropivacaine or bupivacaine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge From PACU</measure>
    <time_frame>Conclusion of surgery until admission to assigned unit or to phase, an expected average of 1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Pain Scale Using FLACC</measure>
    <time_frame>1 hour post-op</time_frame>
    <description>The Face, Legs, Activity, Cry, Consolability scale or FLACC scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Pain Scale Using VAS</measure>
    <time_frame>1 hour post-op</time_frame>
    <description>The visual analogue scale (VAS) for pain is a validated, subjective measure where scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot;</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">281</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Femoral Nerve Blocks</arm_group_label>
    <description>Patients who receive ropivacaine or bupivacaine during femoral nerve block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Femoral nerve block with ropivacaine or bupivacaine</intervention_name>
    <arm_group_label>Femoral Nerve Blocks</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have undergone anesthesia and received a femoral nerve block at Nationwide
        Children'ts Hospital from 2010-2015 utilizing our EMR - PICIS.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status I or II

          -  Age &lt; or equal to 18 years of age at time of femoral nerve block

          -  Femoral nerve block performed from 2010-2015

        Exclusion Criteria:

          -  ASA physical status &gt; II

          -  Co-morbid diseases (cardiac, pulmonary, neurological disease)

          -  Use of adjunctive medications in femoral nerve block (except for epinephrine), such as
             dexamethasone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giorgio Veneziano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <results_first_submitted>February 20, 2018</results_first_submitted>
  <results_first_submitted_qc>November 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2019</results_first_posted>
  <last_update_submitted>November 6, 2018</last_update_submitted>
  <last_update_submitted_qc>November 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Giorgio Veneziano</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Femoral nerve blocks</keyword>
  <keyword>children</keyword>
  <keyword>knee and thigh surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 21, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT02501135/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Femoral Nerve Blocks</title>
          <description>Patients who receive ropivacaine or bupivacaine during femoral nerve block.
Femoral nerve block with ropivacaine or bupivacaine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="281"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="281"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Femoral Nerve Blocks</title>
          <description>Patients who receive ropivacaine or bupivacaine during femoral nerve block.
Femoral nerve block with ropivacaine or bupivacaine</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="281"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" lower_limit="13" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Local Anesthetic Injected for Femoral Nerve Block</title>
        <time_frame>length of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Femoral Nerve Blocks</title>
            <description>Patients who receive ropivacaine or bupivacaine during femoral nerve block.
Femoral nerve block with ropivacaine or bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Local Anesthetic Injected for Femoral Nerve Block</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients who received ropivacaine 0.2%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients who received ropivacaine 0.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients who received bupivacaine 0.25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total mg of Local Anesthetic Injected for Femoral Nerve Block</title>
        <time_frame>length of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Femoral Nerve Blocks</title>
            <description>Patients who receive ropivacaine or bupivacaine during femoral nerve block.
Amount of femoral nerve block with ropivacaine or bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Total mg of Local Anesthetic Injected for Femoral Nerve Block</title>
          <units>ml/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amount of ropivacaine 0.2%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" lower_limit="0.22" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amount of ropivacaine 0.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="0.22" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amount of bupivacaine 0.25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.19" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intraoperative Tylenol Administered</title>
        <description>Amount of Tylenol administered based on if got ropivacaine or bupivacaine femeral nerve block.</description>
        <time_frame>length of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Tylenol Consumption</title>
            <description>Patients who receive ropivacaine or bupivacaine during femoral nerve block and their Tylenol consumptiong during surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Tylenol Administered</title>
          <description>Amount of Tylenol administered based on if got ropivacaine or bupivacaine femeral nerve block.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increased Tylenol use in ropivacaine 0.5% NB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Tylenol use in ropivacaine 0.2% NB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Tylenol use in bupivacaine 0.25% NB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Opioids Administered</title>
        <description>Amount of opioid consumption in the post operative anesthesia care unit depending on if the patient received femoral nerve block with ropivacaine or bupivacaine</description>
        <time_frame>in PACU (1 hr post-op)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post Operative Opioid Consumption</title>
            <description>Patients who receive ropivacaine or bupivacaine during femoral nerve block and their opioid consumption in PACU</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Opioids Administered</title>
          <description>Amount of opioid consumption in the post operative anesthesia care unit depending on if the patient received femoral nerve block with ropivacaine or bupivacaine</description>
          <units>mg/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IV Morphine who got ropivacaine 0.5% nerve block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV Morphine who got ropivacaine 0.2% nerve block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="0" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV Morphine who got bupivacaine 0.25% nerve block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="0" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discharge From PACU</title>
        <time_frame>Conclusion of surgery until admission to assigned unit or to phase, an expected average of 1 hour</time_frame>
        <population>One patient was excluded from analysis of time to PACU discharge due to a missing PACU arrival time.</population>
        <group_list>
          <group group_id="O1">
            <title>Discharge From PACU in Minutes</title>
            <description>The amount of time spent in the post-anesthesia care unit (PACU) in minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discharge From PACU</title>
          <population>One patient was excluded from analysis of time to PACU discharge due to a missing PACU arrival time.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PACU time in pt who got ropivacaine 0.2%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="41" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PACU time in pt who got ropivacaine 0.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="36" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PACU time in pt who got bupivacaine 0.25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="35" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Pain Scale Using FLACC</title>
        <description>The Face, Legs, Activity, Cry, Consolability scale or FLACC scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain.</description>
        <time_frame>1 hour post-op</time_frame>
        <population>63 of the 281 total subjects had their pain assessed using the FLACC pain scale.</population>
        <group_list>
          <group group_id="O1">
            <title>FLACC Pain Scores</title>
            <description>Patients who receive ropivacaine or bupivacaine during femoral nerve block and their FLACC pain scores</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Pain Scale Using FLACC</title>
          <description>The Face, Legs, Activity, Cry, Consolability scale or FLACC scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain.</description>
          <population>63 of the 281 total subjects had their pain assessed using the FLACC pain scale.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FLACC in patient who had ropivacaine 0.2%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLACC in patient who had ropivacaine 0.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLACC in patient who had bupivacaine 0.25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Pain Scale Using VAS</title>
        <description>The visual analogue scale (VAS) for pain is a validated, subjective measure where scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot;</description>
        <time_frame>1 hour post-op</time_frame>
        <population>197 out of the total 281 subjects had their pain assessed using VAS.</population>
        <group_list>
          <group group_id="O1">
            <title>VAS Pain Scores</title>
            <description>Patients who receive ropivacaine or bupivacaine during femoral nerve block and their VAS pain scores</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Pain Scale Using VAS</title>
          <description>The visual analogue scale (VAS) for pain is a validated, subjective measure where scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot;</description>
          <population>197 out of the total 281 subjects had their pain assessed using VAS.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ropivacaine 0.2%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ropivacaine 0.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bupivacaine 0.25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Femoral Nerve Blocks</title>
          <description>Patients who receive ropivacaine or bupivacaine during femoral nerve block.
Femoral nerve block with ropivacaine or bupivacaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Coordinator</name_or_title>
      <organization>Nationwide Children's Hospital</organization>
      <phone>6147222997</phone>
      <email>heather.dellinger@nationwidechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

